Overview

TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (TQ Formula plus nivolumab and ipilimumab) in the second-line setting for GEP-NECA. TQ Formula(TQ, C10H12O2) is the main bioactive component of the black seed (Nigella sativa, Ranunculaceae family) and has anti-oxidant, anti-angiogenic effects.

Phase:

Phase 1

Details

Lead Sponsor:

Amr Mohamed MD

Treatments:

Ipilimumab
Nivolumab